Analyst Price Target is $44.40
▲ +0.57% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Albireo Pharma in the last 3 months. The average price target is $44.40, with a high forecast of $48.00 and a low forecast of $42.00. The average price target represents a 0.57% upside from the last price of $44.15.
Current Consensus is
The current consensus among 6 investment analysts is to hold stock in Albireo Pharma. This Hold consensus rating has held steady for over two years.
Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.